中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2009, 21(2): 270-275
糖尿病和动脉粥样硬化的潜在靶标——FABP4(aP2)
闫桂蕊,张小东,蔡海燕,朱维良,王贺瑶*
中国科学院上海药物研究所,上海201203
摘 要:脂肪细胞型脂肪酸结合蛋白(A-FABP/FABP4/aP2/ALBP)作为脂肪酸结合蛋白家族中的一员,在脂肪细胞和巨噬细胞中高表达。在鼠及人的肥胖个体中FABP4表达均增加。FABP4基因缺陷可改善胰岛素抵抗,并抑制动脉粥样硬化的发生发展。FABP4抑制剂减小了动物体内动脉硬化斑块的大小且提高了胰岛素敏感性。FABP4已经成为治疗糖尿病和动脉粥样硬化的重要潜在靶标。
关键词
:脂肪细胞型脂肪酸结合蛋白;糖尿病;动脉粥样硬化;药物靶标
 
A potential target for diabetes and atherosclerosis: FABP4(aP2)
YAN Gui-rui, Zhang Xiao-dong, Cai Hai-yan, Zhu Wei-liang, Wang He-yao*
Shanghai Institute of Materia Media, Chinese Academy of Science, Shanghai 201213, China
Abstract: Adipocyte fatty-acid-binding protein (A-FABP/FABP4/aP2/ALBP), a member of the intracellular fatty acid binding proteins (FABPs), is primarily located in adipocytes and macrophages. It has been shown that loss of Fabp4 improved insulin resistance and ameliorated atherosclerosis in Fabp4 deficient mice. In addition, inhibitors of FABP4 reduced the size of atherosclerotic lesions and increased insulin sensitivity. Thus, FABP4 has been viewed as a potential therapeutic target in treatment of diabetes and atherosclerosis.
Key words: adipocyte fatty-acid-binding protein;diabetes;atherosclerosis;drug target
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2955188 位访问者,欢迎!